Sage Therapeutics, Inc.: restructuring charge — Sage Therapeutics to cut ~40% of workforce, focus on zuranolone launch and SAGE-718/324

Sage Therapeutics, Inc.

Workforce reduction of ~40%; expected severance charge of $36M-$38M in Q3 2023.
Pipeline prioritization: focus on SAGE-718 and SAGE-324; earlier-stage programs paused.
Planned commercial launch of ZURZUVAE (zuranolone) for postpartum depression in late 2023.
Cash, equivalents, and marketable securities ~$1.0B as of June 30, 2023; expected to fund operations into 2026.
Leadership team realigned to support pipeline and commercial priorities.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Sage Therapeutics, Inc. announced a restructuring with charges of approximately $36 million to $38 million affecting the Company (approximately 40%).

Type: restructuring
Charge: approximately $36 million to $38 million
Affected area: the Company
Headcount: approximately 40%

Exact text from the filing

On August 28, 2023, Sage Therapeutics, Inc. (the “Company”) committed to a plan to reorganize the Company’s business operations and pipeline priorities in order to support goals for long-term business growth, including the planned commercial launch of ZURZUVAE TM (zuranolone) for the treatment of adults with postpartum depression (“PPD”) in late 2023. As part of the reorganization, the Company plans to focus its development efforts on its product candidates SAGE-718 and SAGE-324, pause certain earlier-stage programs, implement a reduction of the Company’s workforce by approximately 40%, and align its leadership team structure to scale with its pipeline and commercial priorities. The Company expects a non-recurring charge for severance and related employee costs associated with the workforce reduction of approximately $36 million to $38 million, primarily incurred in the third quarter of 2023.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001193125-23-225406

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.